Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FavId
- Development stage
- Phase 3
- Lead developer
- MMRGlobal
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
FavId is an investigational therapeutic cancer vaccine developed for the treatment of B-cell non-Hodgkin lymphoma. It is a patient-specific, active immunotherapy designed to stimulate the immune system to recognize and attack malignant B cells by targeting the idiotype protein expressed on their surface. The vaccine consists of recombinant idiotype protein derived from each patient's tumor, combined with an adjuvant (GM-CSF) to enhance immune response. Its mechanism of action involves inducing a targeted immune response against lymphoma cells bearing the unique idiotype antigen.
- Brand names
- FavId
- Other names
- FavId
02
Targets
Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on FavId.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FavId.